Effect of Peptide Modified Combined Chemotherapy Drugs and Gene Nanocomposites on Targeted Therapy of Laryngeal Cancer Stem Cells

Abstract

Objective: Targeted killing of laryngeal cancer stem cells has become a consensus in the treatment of laryngeal cancer. Methods: The chitosan-polyethylene glycol sustained-release nanoparticles (mPEG-CS-cRGD/Bmi-1RNAi-PTX) co-loaded with PTX and Bmi-1RNAi previously constructed were used. The effects of mPEG-CS-cRGD/Bmi-1RNAi-PTX nanoparticles on the proliferation and apoptosis of laryngeal carcinoma Hep-2 cells and laryngeal carcinoma Hep-2 cells in tumor-bearing nude mice models and their safety were confirmed by in vitro and in vivo experiments. The expression ratios of CD133 and C-myc genes before and after treatment with PTX and mPEG-CS-cRGD/Bmi-1RNAi-PTX nanoparticles were compared. Results: Compared with the single application of PTX chemotherapy, the nanoparticles combined with chemotherapy drugs can significantly inhibit the proliferation of laryngeal carcinoma Hep-2 cells, promote apoptosis, and significantly inhibit the growth of transplanted tumors, with biological safety. At the same time, the expression levels of CD133 and C-myc in laryngeal cancer stem cells can be reduced in vitro and in vivo, respectively. Conclusion: cRGD peptide, paclitaxel and Bmi-1RNAi can kill laryngeal cancer stem cells with multiple targets and have overlapping synergistic mechanism.